Biotechnology company Bharat Biotech that operates out of Hyderabad which has been trying hard to get emergency approval for its vaccine dose on children became successful in its attempt. Covaxin dose manufactured by the company was permitted for emergency usage for the age group of 2-18.
Having completed the phase 2 and 3 of clinical trials of the Covaxin dose, the pharma company had applied for the emergency use in September. Looking at the data, the Subject Expert Committee gave its nod for the emergency use of vaccines for children.
During its study, the company had tried the vaccine dose on more than 500 people in the second and third phases. The volunteers were given doses with a gap of 28 days. Satisfied with the data, the Hyderabad company had moved the Drugs and Comptroller General of India (DCGI).
It's a proud moment for the Bharat Biotech company as the vaccine developed by it emerged as the first vaccine produced in India that can be given to children to beat the virus. In total, Covaxin is the second dose that can be used for children.
Earlier, the ZyCoV-D dose was approved by the DCGI for children. Despite getting approval for emergency use, the vaccine could not be administered in India due to the delay in the production of the vaccine doses.
Having completed the phase 2 and 3 of clinical trials of the Covaxin dose, the pharma company had applied for the emergency use in September. Looking at the data, the Subject Expert Committee gave its nod for the emergency use of vaccines for children.
During its study, the company had tried the vaccine dose on more than 500 people in the second and third phases. The volunteers were given doses with a gap of 28 days. Satisfied with the data, the Hyderabad company had moved the Drugs and Comptroller General of India (DCGI).
It's a proud moment for the Bharat Biotech company as the vaccine developed by it emerged as the first vaccine produced in India that can be given to children to beat the virus. In total, Covaxin is the second dose that can be used for children.
Earlier, the ZyCoV-D dose was approved by the DCGI for children. Despite getting approval for emergency use, the vaccine could not be administered in India due to the delay in the production of the vaccine doses.